Collaborating with leading scientific institutions worldwide, including Imperial College London and Johns Hopkins University, the Foundation has been responsible for some of the greatest breakthroughs in psychedelic science, including pioneering brain imaging studies on LSD, psilocybin, DMT, and MDMA, as well as clinical trials into psilocybin for depression and addiction, and more recently, laboratory-based research into the potential benefits of microdosing.
Amanda and her team have played a key role in the drafting of the new initiative (v4.3), contributing, in particular, to provisions concerning therapeutic/medical research and treatment. We are most grateful for the knowledge and expertise they bring to the campaign.
|
|